

LAUREN C. BRESEE (nee: BROWN), BScPharm, MSc, PhD, ACPR

I. Biographical Data

Work address: 865 Carling Avenue, Suite 600
Ottawa ON K1S 5S8

Telephone: 1-866-988-1444, ext. 1519 (office)
Cell: (403) 472-2517

E-mail: LaurenB@cadth.ca

Present positions: Scientific Advisor
Canadian Agency for Drugs and Technologies in
Health (CADTH)

Adjunct Assistant Professor, Department of
Community Health Sciences, Cumming School of
Medicine
University of Calgary

Member, O'Brien Institute for Public Health
University of Calgary

February 2016

II. Academic Record:

- 2010 - 2012 Post-Doctoral Fellow
Alberta Kidney Disease Network
University of Calgary
Calgary, Alberta, Canada
- 2005 – 2010 Doctor of Philosophy
School of Public Health
University of Alberta
Edmonton, Alberta, Canada
Specialization: Clinical Epidemiology
- 2002 – 2005 Master of Science
Medical Sciences-Public Health Sciences
University of Alberta
Edmonton, Alberta, Canada
Specialization: Clinical Epidemiology
- 2001 –2002 Accredited Canadian Pharmacy Resident
Capital Health Authority
Edmonton, Alberta, Canada
- 1997 – 2001 Bachelor of Science in Pharmacy
Faculty of Pharmacy and Pharmaceutical Sciences
University of Alberta
Edmonton, Alberta, Canada

Additional educational courses

- 2011 McGill University
Pharmacoepidemiology IV: Pharmacoeconomics 654
Montreal, Quebec, Canada
- 2010 Foundations of Project Management I
Mitacs
- 2008 McGill University
Advanced Pharmacoepidemiology 661
Montreal, Quebec, Canada
- 2005 Centers for Disease Control and Prevention (CDC) Short Course:
Diabetes Public Health and Research
Atlanta, Georgia, United States of America

Pharmacy Licensure

2001 - Present Alberta College of Pharmacists

III. Awards and Distinctions

2016 Patient Care Enhancement Award
Canadian Society of Hospital Pharmacists

2015 Past President Award
Canadian Society of Hospital Pharmacists – Alberta Branch

2011 4th ICPC/HSFC/CCS Fellowship in Preventive Cardiology
Heart and Stroke Foundation of Canada

2011 Full-time Fellowship
Alberta Innovates - Health Solutions

2010 Best Clinical Abstract Award
Cardiac Sciences Research Day
University of Alberta

2008 - 2010 Clinical Fellowship
Canadian Institutes of Health Research

2007 Best Student Oral Presentation
School of Public Health Research Symposium
University of Alberta

2006 Best Student Oral Presentation
Canadian Association of Population Therapeutics

2006 Community Service/Leadership Award for Doctoral Students
PHS Alumni Association

2005 - 2008 Studentship
Alberta Heritage Foundation for Medical Research

2005 - 2006 Education Grant
Canadian College of Clinical Pharmacy

2005 Best Poster Presentation Award
Department of Public Health Sciences Research Day

2005 Studentship

	Alberta Diabetes Institute (Honorary; declined due to acceptance of AHFMR Studentship)
2004	Future of Pharmacy Award Pharmacist's Association of Alberta
2004	Best Poster Presentation Award Canadian Society of Hospital Pharmacists, Banff Seminar
2002 - 2003	Scholarship Award Canadian Society of Hospital Pharmacists
2002	Best Case Presentation and Research Project Presentation Aventis Pharmacy Resident Award
2001	Citizenship Award Alberta Pharmaceutical Association/Alberta Pharmacy Students' Association
2000	Centennial Scholar Canadian Pharmacists Association
1996 - 1997	Jimmy Condon Athletic Scholarship

IV. Professional Experience

2015 – Present	Scientific Advisor Canadian Agency for Drugs and Technologies in Health (CADTH) Ottawa, Ontario
2013 – Present	Adjunct Assistant Professor Cumming School of Medicine, Department of Community Health Sciences University of Calgary Calgary, Alberta
2012 – 2015	Drug Stewardship Pharmacist, Calgary Zone Alberta Health Services Calgary, Alberta
2011 - Present	Collaborator Canadian Network for Observational Drug Effect Studies (CNODES) Drug Safety and Effectiveness Network (DSEN) University of Calgary

2011 - 2015	Contractor Canadian Agency for Drugs and Technologies in Health (CADTH) Ottawa, Ontario
2010 - 2015	Residency Research Advisor, Calgary and Cancer Corridor Alberta Health Services Calgary, Alberta
2007 – 2010	Clinical Pharmacist Calgary Foothills Primary Care Network Calgary, Alberta
2005 – 2010	Graduate Research Associate Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD) Edmonton, Alberta
2005 – 2007	Contributor: Development of Continuing Education Programs Office of Continuing Pharmacy Education Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta Edmonton, Alberta
2005 – 2007	Clinical Pharmacist, Casual Grey Nuns Community Hospital and Healthcare Centre Edmonton, Alberta
2002 – 2005	Clinical Pharmacist, Psychiatry Grey Nuns Community Hospital and Healthcare Centre Edmonton, Alberta

V. Teaching Experience / Educational Activities

2002 – 2012	Lecturer at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Endocrinology Module <ul style="list-style-type: none"> • Introduction to Diabetes • Management of Type 1 Diabetes
-------------	---

Fellow Involvement

2014 Dr. Nipunie Rajapakse

- Pediatric Antimicrobial Stewardship Fellow
- On fellowship committee and provide research methodology support for Dr. Rajapakse

Master of Science in Epidemiology Students

2015 – Present Lauren Hirsch

- Member of Ms. Hirsch’s supervisory committee

2013 – 2015 Keltie McDonald

- Member of Ms. McDonald’s supervisory committee

Summer Student Supervision

2015 Robert Wright

- BScPharm Student, University of Alberta, Edmonton, Alberta

2014 Sandra MacTavish

- BscPharm Student, University of Waterloo, Waterloo, Ontario

2012 Sundus Khan

- BSc student, University of Calgary, Calgary, Alberta

2011 Melissa Schorr

- MD student, Royal College of Surgeons in Ireland, Dublin, Ireland

VI. Professional Activities

i. Membership in professional and learned societies

2014 – present O’Brien Institute for Public Health, University of Calgary

2008 – present International Society of Psychiatric Epidemiology
Associate member

1998 – present Canadian Society of Hospital Pharmacists

ii. Professional service

2016 – Present: Vice-Chair, Research Committee, Canadian Society of Hospital Pharmacists

2013 – Present: Presidential Officer, Canadian Society of Hospital Pharmacists, Alberta Branch

2012 – 2013: Co-Chair, Canadian Society of Hospital Pharmacists, Summer Educational Session
2013 Conference

2010 – 2011: Government of Alberta, Personal Health Portal Steering Committee, Public Member

2007 – 2008: Canadian Society of Hospital Pharmacists, Alberta Branch, Education Committee

2006 – 2013: Canadian Society of Hospital Pharmacists, Practice Standards Steering Committee

2006 – 2007: University of Alberta, Health Services Advisory Group

2005 – 2008: Canadian Society of Hospital Pharmacists, Awards Program Appraiser

2002 – 2005: Canadian Society of Hospital Pharmacists, Alberta Branch, Capital Chapter Chair

2003 – 2004: Canadian Society of Hospital Pharmacists, Banff Seminar Planning Committee

1999 – 2000: Alberta Pharmacy Students' Association, President

1999 – 2000: Canadian Association of Pharmacy Students and Interns, Alberta Senior Representative

Journal Reviews:

Canadian Journal of Hospital Pharmacy
Canadian Journal of Psychiatry
Circulation
CMAJ
CMAJ Open
Diabetes Research and Clinical Practice
Diabetologia
Ethnicity & Disease
General Hospital Psychiatry
International Clinical Psychopharmacology
Journal of Clinical Psychopharmacology
Psychiatric Services
Schizophrenia Bulletin
Schizophrenia Research

VII. Invited Presentations

1. "The Canadian Network of Observational Drug Effect Studies". Canadian Society of Hospital Pharmacists, Summer Educational Sessions, 2013.
2. "An introduction to survey methodology". Canadian Society of Hospital Pharmacists, Professional Practice Conference, 2013.
3. "Balancing efficacy and side effects: The relationship between schizophrenia, atypical antipsychotic agents, and metabolic abnormalities". Canadian Society of Hospital Pharmacists, Professional Practice Conference, 2011.
4. "Metabolic abnormalities associated with atypical antipsychotic agents: How do the new agents compare?". Canadian Society of Hospital Pharmacists, Alberta Branch Annual General Meeting, 2010.

5. "The relationship between depression and type 2 diabetes". Palliser Primary Care Network Diabetes Education Conference, November 2010.
6. "The metabolic effects of atypical antipsychotic agents – getting to the heart of the matter". Canadian Society of Hospital Pharmacists Banff Seminar, March 2009.
7. "The relationship between depression and diabetes". A Consensus Development Conference on Depression in Adults: How to Improve Prevention, Diagnosis, and Treatment, Calgary, Alberta, October 2008.
8. "Pharmacotherapy of Obesity". National Obesity Certificate Program, September 2008.
9. "Mental illness, atypical antipsychotics, and metabolic abnormalities: How do we minimize cardiovascular risk?". Canadian Society of Hospital Pharmacists: Alberta Branch Annual General Meeting, October 2007.
10. "Basic Evidence Based Medicine Workshop". Canadian Cardiovascular Pharmacists Network 5th Annual Meeting. September 2005.
11. "Depression – An Overlooked Comorbidity of Diabetes". Manitoba Pharmacy Conference, Oral Presentation, April 2005.

VIII. Published Refereed Manuscripts

1. Heck T, Gunther M, **Bresee L**, Mysak T, McMillan C, Koshman S. Independent prescribing by hospital pharmacists: Patterns and Practices in a Canadian Province. *Am J Health Syst Pharm* 2015;72:2166-2175.
2. Dalton BR, MacTavish SJ, **Bresee LC**, Rajapakse N, Vanderkooi O, Vayalumkal J, Conly J. Antimicrobial use over a four-year period using days of therapy measurement at a Canadian pediatric acute care hospital. *Canadian Journal of Infectious Diseases and Medical Microbiology* 2015;26:253-258.
3. Renoux C, Lix LM, Patenaude V, **Bresee LC**, Paterson JM, Lafrance J-P, Tamim H, Mahmud SM, Alsabbagh W, Hemmelgarn B, Dormuth CR, Ernst P, and the CNODES Investigators. Serotonin-norepinephrine reuptake inhibitors and the risk of acute kidney injury: a cohort study of eight administrative databases and meta-analysis. *Clinical Journal of the American Society of Nephrology* 2015;10:1716-1722.
4. Dalton BR, Sabuda DM, **Bresee LC**, Conly JM. Use of an electronic medication administration record for surveillance of medication omissions: results of a one year study of antimicrobials in the inpatient setting. *PLoS ONE* 10(4): e0122422. doi:10.1371/journal.pone.0122422.

5. Dalton BR, Sabuda DM, **Bresee LC**, Conly JM. Assessment of antimicrobial utilization metrics; days of therapy versus defined daily doses and pharmacy dispensing records versus nursing administration data. *Infection Control & Hospital Epidemiology* 2015;36:688-694.
6. McDonald K, Bulloch AGM, Duffy AC, **Bresee LC**, Williams J, Lavorato D, Patten SB. Prevalence of bipolar I and II disorder in Canada. *Canadian Journal of Psychiatry* 2015;60:151-156.
7. Pasay DK, Chow S, **Bresee LC**, Guirguis M, Slobodan J. Assessment of current antimicrobial stewardship policies and resources: a focus group project. *Healthcare Infection* 2015; 20:7-15.
8. Hoang J, **Bresee LC**, Kraft T, Vanderkooi OG, Dersch-Mills D. Achieving therapeutic vancomycin levels in pediatric patients. *Canadian Journal of Hospital Pharmacy* 2014;67:416-422.
9. **Bresee LC**. An introduction to developing surveys for pharmacy practice research. *Canadian Journal of Hospital Pharmacy* 2014;67:286-291.
10. Todd RA, Lewin AM, **Bresee LC**, Southern D, Rabi DM. Coronary artery disease in adults with schizophrenia: anatomy, treatment, and outcomes. *IJC Heart & Vessels* 2014;4:84-89.
11. **Bresee LC**, Knudtson ML, Tonelli M, Crowshoe L, Quan H, Ghali W, Ahmed S, Zhang J, Manns B, Hemmelgarn BR. Access to and outcomes after coronary angiography for First Nations people with acute myocardial infarction. *CMAJ* 2014;186:E372-E380.
12. Lipscombe LL, Austin PC, Alessi-Severini S, Blackburn DF, Blais L, **Bresee LC**, Filion KB, Kawasumi Y, Kurdyak P, Platt RW, Tamim H, Paterson JM, and the Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data. *Schizophrenia Research* 2014;154:54-60.
13. Blackburn DF, Tran D, Crawley A, Lynds S, Champagne A, **Bresee L**, Remillard AJ. Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan? *J Popul Ther Clin Pharmacol* 2014;21:e31-e37.
14. Schorr M, Hemmelgarn BR, Tonelli M, Soo A, Manns BJ, **Bresee LC** for the Alberta Kidney Disease Network. Assessment of serum creatinine and kidney function among incident metformin users. *Canadian Journal of Diabetes* 2013;37:226-230.
15. Patten SB, Waheed W, **Bresee LC**. A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents. *Canadian Journal of Psychiatry* 2012;57:717-721.

16. Bulloch AGM, **Bresee LC**, Beck CA, Patten SB. Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002-2010. *Canadian Journal of Psychiatry* 2012; 57:263-268.
17. Conley J, Tonelli M, Quan H, Manns BJ, Palacios L, **Bresee LC**, Kahn N, Hemmelgarn BR, for the Alberta Kidney Disease Network. Association between glomerular filtration rate, proteinuria and adverse outcomes among White, Chinese and South Asian patients. *American Journal of Kidney Diseases* 2012;59:390-399.
18. **Bresee LC**, Majumdar SR, Patten SB, Johnson JA. Utilization of general and specialized cardiac care in people with schizophrenia. *Psychiatric Services* 2012;63:237-242.
19. **Bresee LC**, Majumdar SR, Patten SB, Johnson JA. Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. *European Psychiatry* 2011;26:327-332.
20. **Bresee LC**, Majumdar SR, Patten SB, Johnson JA. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. *Schizophrenia Research* 2010;117:75-82.
21. Richter CA, Kalenga JCM, Rowe BH, **Bresee LC**, Tsuyuki RT. Practice patterns and outcomes in patients presenting to the emergency department with acute heart failure. *Canadian Journal of Cardiology* 2009; 25:e173-e178.
22. Patten SB, Williams JVA, Lavorate DH, **Brown L**, McLaren L, Eliasziw M. Major depression, antidepressant medication and the risk of obesity. *Psychotherapy and Psychosomatics* 2009;78:182-186.
23. Gamble JM, Simpson SH, **Brown LC**, Johnson JA. Insulin versus an oral antidiabetic agent as add-on therapy in patients with type 2 diabetes failing their current oral antidiabetic regimen. *Open Medicine* 2008;2:1-13.
24. **Brown LC**, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. *Diabetes Research and Clinical Practice* 2008;79:61-67.
25. Newman SC, Gardner DM, **Brown LC**, Tsuyuki RT. Improving the use of antidepressants in the community: The design of A Cohort and Intervention Study Evaluating Antidepressant Epidemiology and Adherence (ACHIEVA). *Canadian Pharmacists Journal* 2007;40:175-179.
26. **Brown LC**, Majumdar SR, Newman SC, Johnson JA. Type 2 diabetes does not increase risk of depression. *CMAJ* 2006;175:42-46. (with accompanying editorial: Wexler DJ. Low risk of depression in diabetes? Would that it were so. *CMAJ* 2006;175:47-48).
27. **Brown LC**, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. *Diabetes Care* 2005;28:1063-1067.

28. **Brown LC**, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of sub-optimal cardiovascular risk management in patients with type 2 diabetes and symptomatic atherosclerosis. *CMAJ* 2004;171:1189-1192.

Manuscripts Submitted:

1. Bonazza S, **Bresee LC**, Kraft T, Ross BC, Dersch-Mills D. Frequency of and risk factors for acute kidney injury associated with vancomycin use in the pediatric intensive care unit. Under review: *The Pediatric Infectious Disease Journal*.

Reports and Book Chapters:

1. Betamethasone for adults with scalp psoriasis: a review of the clinical and cost-effectiveness. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), March 30, 2015. Available from: <https://www.cadth.ca/sites/default/files/pdf/htis/apr-2015/RC0645%20Betamethasone%20Final.pdf>
2. Hydroxyethyl starch use for patients with postpartum hemorrhage: a review of clinical effectiveness, safety, and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), September 17, 2014. Available from: <http://www.cadth.ca/media/pdf/htis/oct-2014/RC0587%20Hydroxyethyl%20starch%20Final.pdf>
3. Periodic dental examinations for oral health: a review of clinical effectiveness, cost-effectiveness, and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), May 14, 2014. Available at: <http://www.cadth.ca/media/pdf/htis/sep-2014/RC0555%20Dental%20Recall%20Final.pdf>
4. Bariatric surgical procedures for obese and morbidly obese patients: a review of comparative clinical and cost-effectiveness, and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), April 16, 2014. Available at: <http://www.cadth.ca/media/pdf/htis/jun-2014/RC0544-000%20Bariatric%20Surgery%20Final.pdf>
5. Endoscopy ultrasound for the diagnosis of disease and staging of cancers in adult patients with gastroenterological or oncological disease: a review of the clinical effectiveness, cost-effectiveness and safety. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), March 18, 2014. Available at: <http://www.cadth.ca/media/pdf/htis/nov-2014/RC0535%20Endoscopic%20Ultrasound%20Final.pdf>
6. Peripherally inserted central catheters (PICCs) for adult and pediatric patients: a review of clinical evidence. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), April 5, 2013. Available at:

<http://www.cadth.ca/media/pdf/htis/may-2013/RC0442%20PICCs%20for%20Adults%20and%20Pediatrics%20Final.pdf>

7. Thrombolytic drugs for cardiac arrest: a review of the clinical effectiveness. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), January 28, 2013. Available at: <http://cadth.ca/media/pdf/htis/jan-2013/RC0422%20Thrombolytics%20for%20cardiac%20arrest%20Final.pdf>
8. Sterilization equipment and requirements for endoscopy equipment: a review of clinical evidence and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), January 19, 2012. Available at: <http://cadth.ca/media/pdf/htis/jan-2012/RC0314%20Endoscopy%20%20Sterilization%20Final.pdf>
9. Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness, and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), November 15, 2011. Available at: <http://www.cadth.ca/media/pdf/htis/nov-2011/RC0307-000%20Varicose%20Veins.pdf>
10. Interferon-gamma release assays testing versus tuberculosis skin testing for tuberculosis: a review of the clinical effectiveness and guidelines. Rapid Response report produced for the Canadian Agency of Drugs and Technologies in Health (CADTH), May 25, 2011. Available at: http://www.cadth.ca/media/pdf/htis/may-2011/RC0273_Interferon_Gamma_Final.pdf.
11. **Bresee LC**, Clement F, Tan Z, Manns BJ, Tonelli M, Hemmelgarn BR. Chapter 5: Use of indicated laboratory testing among people with diabetes in Alberta. In Johnson JA, editor, *Alberta Diabetes Atlas 2011*. Edmonton: Institute of Health Economics; 2011: 59-74.
12. **Bresee LC**, Svenson LW, Patten SB. Chapter 10: Diabetes and mental health disorders in Alberta. In Johnson JA, editor, *Alberta Diabetes Atlas 2011*. Edmonton: Institute of Health Economics; 2011: 163-176.
13. **Bresee LC**, Svenson LW, Patten SB. Diabetes and mental health disorders in Alberta. In Johnson JA, editor, *Alberta Diabetes Atlas 2009*. Edmonton: Institute of Health Economics 2009:175-187.
14. **Brown LC**, Svenson LW, Beck CA. Diabetes and Mental Health Disorders in Alberta: In *Alberta Diabetes Atlas 2007*: Institute of Health Economics:p.113-125.